Dirk Schrijvers
Research Subjects
Research Interests
Dirk Schrijvers has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Jan Baptist Vermorken
Antwerp University Hospital
3 shared publications - Pol Specenier
Department of Oncology, University Hospital Antwerp, Edegem, Belgium
2 shared publications Sevilay Altintas
University Hospital Antwerp
2 shared publications- Abdelbari Baitar
Department of Medical Oncology, ZNA Middelheim, Antwerp, Belgium
1 shared publication Ahmad Awada
Jules Bordet Institute, Bruxelles, Belgium
1 shared publication- Alain Bols
Department of Oncology, AZ Sint-Jan, Brugge, Belgium
1 shared publication
Latest Publications
- 8 November 2023
- Published by Springer Nature
- p. 1-48
Gynecologic Cancer
- Open Access
End-of-Life Care in the Last Three Months before Death in Older Patients with Cancer in Belgium: A Large Retrospective Cohort Study Using Data Linkage
This study aims to describe end-of-life (EOL) care in older patients with cancer and investigate the association between geriatric assessment (GA) results and specialized palliative care (SPC) use. Older patients with a new cancer diagnosis (2009–2015) originally included in a previous multicentric study were selected if they died before the end of follow-up (2019). At the time of cancer diagnosis, patients underwent geriatric screening with Geriatric 8 (G8) followed by GA in case of a G8 score ≤14/17. These data were linked to the cancer registry and healthcare reimbursement data for follow-up. EOL care was assessed in the last three months before death, and associations were analyzed using logistic regression. A total of 3546 deceased older patients with cancer with a median age of 79 years at diagnosis were included. Breast, colon, and lung cancer were the most common diagnoses. In the last three months of life, 76.3% were hospitalized, 49.1% had an emergency department visit, and 43.5% received SPC. In total, 55.0% died in the hospital (38.5% in a non-palliative care unit and 16.4% in a palliative care unit). In multivariable analyses, functional and cognitive impairment at cancer diagnosis was associated with less SPC. Further research on optimizing EOL healthcare utilization and broadening access to SPC is needed.
Open AccessEnd-of-Life Care in the Last Three Months before Death in Older Patients with Cancer in Belgium: A Large Retrospective Cohort Study Using Data Linkage
This study aims to describe end-of-life (EOL) care in older patients with cancer and investigate the association between geriatric assessment (GA) results and specialized palliative care (SPC) use. Older patients with a new cancer diagnosis (2009–2015) originally included in a previous multicentric study were selected if they died before the end of follow-up (2019). At the time of cancer diagnosis, patients underwent geriatric screening with Geriatric 8 (G8) followed by GA in case of a G8 score ≤14/17. These data were linked to the cancer registry and healthcare reimbursement data for follow-up. EOL care was assessed in the last three months before death, and associations were analyzed using logistic regression. A total of 3546 deceased older patients with cancer with a median age of 79 years at diagnosis were included. Breast, colon, and lung cancer were the most common diagnoses. In the last three months of life, 76.3% were hospitalized, 49.1% had an emergency department visit, and 43.5% received SPC. In total, 55.0% died in the hospital (38.5% in a non-palliative care unit and 16.4% in a palliative care unit). In multivariable analyses, functional and cognitive impairment at cancer diagnosis was associated with less SPC. Further research on optimizing EOL healthcare utilization and broadening access to SPC is needed.
- Open Access
- 4 March 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 769003
Palliative Care and End-of-Life Issues in Elderly Cancer Patients With Head and Neck Cancer
The number of elderly patients with incurable head and neck cancer will increase. They are in need of geriatric palliative care, that takes into account oncology, palliative care and geriatric medicine. In this review of the most recent and relevant literature and includes the expert opinion of the authors, several physical problems (e.g. pain, fatigue, malnutrition, and loco-regional problems) encountered by the elderly head and neck cancer patients are addressed. In addition end-of life issues in this patient population are discussed.
- 4 March 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 769003
Open AccessPalliative Care and End-of-Life Issues in Elderly Cancer Patients With Head and Neck Cancer
The number of elderly patients with incurable head and neck cancer will increase. They are in need of geriatric palliative care, that takes into account oncology, palliative care and geriatric medicine. In this review of the most recent and relevant literature and includes the expert opinion of the authors, several physical problems (e.g. pain, fatigue, malnutrition, and loco-regional problems) encountered by the elderly head and neck cancer patients are addressed. In addition end-of life issues in this patient population are discussed.
- 28 June 2018
- Published by Springer Nature
- p. 121-178
Gynecologic Cancer
- Open Access
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis
Background: There are multiple existing and emerging therapeutic avenues for metastatic prostate cancer, with a common denominator, which is the need for predictive biomarkers. Circulating tumor DNA (ctDNA) has the potential to cost-efficiently accelerate precision medicine trials to improve clinical efficacy and diminish costs and toxicity. However, comprehensive ctDNA profiling in metastatic prostate cancer to date has been limited. Methods: A combination of targeted- and low-pass whole genome sequencing was performed on plasma cell-free DNA and matched white blood cell germline DNA in 364 blood samples from 217 metastatic prostate cancer patients. Results: ctDNA was detected in 85.9% of baseline samples, correlated to line of therapy and was mirrored by circulating tumor cell enumeration of synchronous blood samples. Comprehensive profiling of the androgen receptor (AR) revealed a continuous increase in the fraction of patients with intra- AR structural variation, from 15.4% during first line mCRPC therapy to 45.2% in fourth line, indicating a continuous evolution of AR during the course of the disease. Patients displayed frequent alterations in DNA repair deficiency genes (18.0%). Additionally, the microsatellite instability phenotype was identified in 3.81% of eligible samples (≥0.1 ctDNA fraction). Sequencing of non-repetitive intronic- and exonic regions of PTEN, RB1 and TP53 detected biallelic inactivation in 47.5%, 20.3% and 44.1% of samples with ≥0.2 ctDNA fraction, respectively. Only one patient carried a clonal high-impact variant without a detectable second hit. Intronic high-impact structural variation was twice as common as exonic mutations in PTEN and RB1. Finally, 14.6% of patients presented false positive variants due to clonal hematopoiesis, commonly ignored in commercially available assays. Conclusions: ctDNA profiles appear to mirror the genomic landscape of metastatic prostate cancer tissue and may cost-efficiently provide somatic information in clinical trials designed to identify predictive biomarkers. However, intronic sequencing of the interrogated tumor suppressors challenge the ubiquitous focus on coding regions and is vital, together with profiling of synchronous white blood cells, to minimize erroneous assignments which in turn may confound results and impede true associations in clinical trials.
Open AccessCell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis
Background: There are multiple existing and emerging therapeutic avenues for metastatic prostate cancer, with a common denominator, which is the need for predictive biomarkers. Circulating tumor DNA (ctDNA) has the potential to cost-efficiently accelerate precision medicine trials to improve clinical efficacy and diminish costs and toxicity. However, comprehensive ctDNA profiling in metastatic prostate cancer to date has been limited. Methods: A combination of targeted- and low-pass whole genome sequencing was performed on plasma cell-free DNA and matched white blood cell germline DNA in 364 blood samples from 217 metastatic prostate cancer patients. Results: ctDNA was detected in 85.9% of baseline samples, correlated to line of therapy and was mirrored by circulating tumor cell enumeration of synchronous blood samples. Comprehensive profiling of the androgen receptor (AR) revealed a continuous increase in the fraction of patients with intra- AR structural variation, from 15.4% during first line mCRPC therapy to 45.2% in fourth line, indicating a continuous evolution of AR during the course of the disease. Patients displayed frequent alterations in DNA repair deficiency genes (18.0%). Additionally, the microsatellite instability phenotype was identified in 3.81% of eligible samples (≥0.1 ctDNA fraction). Sequencing of non-repetitive intronic- and exonic regions of PTEN, RB1 and TP53 detected biallelic inactivation in 47.5%, 20.3% and 44.1% of samples with ≥0.2 ctDNA fraction, respectively. Only one patient carried a clonal high-impact variant without a detectable second hit. Intronic high-impact structural variation was twice as common as exonic mutations in PTEN and RB1. Finally, 14.6% of patients presented false positive variants due to clonal hematopoiesis, commonly ignored in commercially available assays. Conclusions: ctDNA profiles appear to mirror the genomic landscape of metastatic prostate cancer tissue and may cost-efficiently provide somatic information in clinical trials designed to identify predictive biomarkers. However, intronic sequencing of the interrogated tumor suppressors challenge the ubiquitous focus on coding regions and is vital, together with profiling of synchronous white blood cells, to minimize erroneous assignments which in turn may confound results and impede true associations in clinical trials.
- 10 December 2016
- Published by Springer Nature
- p. 263-271
Palliative Care in Patients with Head and Neck Cancer
- 10 December 2016
- Published by Springer Nature
- p. 263-271
Palliative Care in Patients with Head and Neck Cancer
- 10 December 2016
- Published by Springer Nature
- p. 281-285
Symptoms at End-of-Life of Head and Neck Cancer Patients
- 10 December 2016
- Published by Springer Nature
- p. 281-285
Symptoms at End-of-Life of Head and Neck Cancer Patients
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 6076
TPF plus cetuximab (E) induction chemotherapy (ICT) followed by biochemoradiation (BCRT) with weekly E plus weekly cisplatin (P) or carboplatin (C) in stage III/IV squamous cell carcinoma of the head and neck (HNSCC): A randomized phase II EORTC trial.
6076 Background: To test the safety of BCRT with P and C after TPF-E. Methods: Stage III/IV unresectable, HNSCC pts received up to 4 cycles (cy) of TPF-E (P and docetaxel [D] 75 mg/m² d 1, 5-FU 750 mg/m²/d d1-5, cetuximab [E, 400/250 mg/m²/wk]), with prophylactic antibiotics, no G-CSF. Pts with no PD after 4 cy were randomly assigned to BCRT (70 Gy/7 weeks/2 Gy fractions), weekly E, with either P 40 mg/m²/wk or C AUC 1.5/wk. Primary endpoint: feasibility of BCRT ( > 80% dose intensity (DI) of RT, P or C, and E). Results: 46 patients started TPF-E, 30 started BCRT. Median age: 57 (48-72), 41 male. WHO 0/1: 29/17. Stage III/IV: 4/42. 4 oral cavity, 24 oropharynx, 12 hypopharynx, 4 larynx, 2 unknown. 34, 4, 6, 2 pts received 4,3,2, and 1 TPF-E cy. Median DI (mg/m²/wk): D: 24.4, P: 24.4, 5-FU: 1220.9, E: 255.4. ICT was discontinued in 12 pts (6 toxicity [1 grade 5], 1 protocol violation, 2 medical decision, 1 pt refusal, 1 death [cause unknown], 1 cerebrovascular accident). 3 were not randomized: 1 PD under ICT, 1 RT start prior to randomization, 1 co-morbidity/TPF-E toxicity. Median DI on BCRT (mg/m²/wk): P arm: P: 34.4, E: 238.1; C arm: C: AUC 1.5/wk, E: 243.2. P and C were stopped early in 7 and 4 pts, respectively. RT was stopped in 2 pts with P and interrupted in 1 and 4 pts with P and C, respectively. Conclusions: Only 34/46 pts completed 4 TPF-E. 30/46 started BCRT. 53 % and 47 % of the randomized pts failed to meet the feasibility criteria with P and C, respectively. Study closed prematurely. Clinical trial information: NCT00646659.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 6076
TPF plus cetuximab (E) induction chemotherapy (ICT) followed by biochemoradiation (BCRT) with weekly E plus weekly cisplatin (P) or carboplatin (C) in stage III/IV squamous cell carcinoma of the head and neck (HNSCC): A randomized phase II EORTC trial.
6076 Background: To test the safety of BCRT with P and C after TPF-E. Methods: Stage III/IV unresectable, HNSCC pts received up to 4 cycles (cy) of TPF-E (P and docetaxel [D] 75 mg/m² d 1, 5-FU 750 mg/m²/d d1-5, cetuximab [E, 400/250 mg/m²/wk]), with prophylactic antibiotics, no G-CSF. Pts with no PD after 4 cy were randomly assigned to BCRT (70 Gy/7 weeks/2 Gy fractions), weekly E, with either P 40 mg/m²/wk or C AUC 1.5/wk. Primary endpoint: feasibility of BCRT ( > 80% dose intensity (DI) of RT, P or C, and E). Results: 46 patients started TPF-E, 30 started BCRT. Median age: 57 (48-72), 41 male. WHO 0/1: 29/17. Stage III/IV: 4/42. 4 oral cavity, 24 oropharynx, 12 hypopharynx, 4 larynx, 2 unknown. 34, 4, 6, 2 pts received 4,3,2, and 1 TPF-E cy. Median DI (mg/m²/wk): D: 24.4, P: 24.4, 5-FU: 1220.9, E: 255.4. ICT was discontinued in 12 pts (6 toxicity [1 grade 5], 1 protocol violation, 2 medical decision, 1 pt refusal, 1 death [cause unknown], 1 cerebrovascular accident). 3 were not randomized: 1 PD under ICT, 1 RT start prior to randomization, 1 co-morbidity/TPF-E toxicity. Median DI on BCRT (mg/m²/wk): P arm: P: 34.4, E: 238.1; C arm: C: AUC 1.5/wk, E: 243.2. P and C were stopped early in 7 and 4 pts, respectively. RT was stopped in 2 pts with P and interrupted in 1 and 4 pts with P and C, respectively. Conclusions: Only 34/46 pts completed 4 TPF-E. 30/46 started BCRT. 53 % and 47 % of the randomized pts failed to meet the feasibility criteria with P and C, respectively. Study closed prematurely. Clinical trial information: NCT00646659.
- Open Access
- 25 June 2015
- Published by Elsevier
- Vol. 26 (9) , 2003-2005
Does activity of anticancer drugs in advanced cancer always translates in effectivity in early-stage high-risk disease?
- 25 June 2015
- Published by Elsevier
- Vol. 26 (9) , 2003-2005
Open AccessDoes activity of anticancer drugs in advanced cancer always translates in effectivity in early-stage high-risk disease?
- Open Access
- 16 May 2015
- Published by Bio Accent Group LLC
- Vol. 1 (1) , 1-7
Clinical Trials at the End-of-life
- 16 May 2015
- Published by Bio Accent Group LLC
- Vol. 1 (1) , 1-7
Open AccessClinical Trials at the End-of-life